Intravenous enoxaparin as alternative ECMO anticoagulation over a period of 94 days: a case report
Language English Country England, Great Britain Media electronic
Document type Case Reports, Journal Article
Grant support
No. 00064203
Ministry of Health, the Czech Republic - Conceptual Development of Research Organization, Motol University Hospital, Prague
No. 00064203
Ministry of Health, the Czech Republic - Conceptual Development of Research Organization, Motol University Hospital, Prague
No. 00064203
Ministry of Health, the Czech Republic - Conceptual Development of Research Organization, Motol University Hospital, Prague
No. 00064203
Ministry of Health, the Czech Republic - Conceptual Development of Research Organization, Motol University Hospital, Prague
PubMed
37041623
PubMed Central
PMC10088682
DOI
10.1186/s13019-023-02226-0
PII: 10.1186/s13019-023-02226-0
Knihovny.cz E-resources
- Keywords
- ECMO, Enoxaparin, Extracorporeal membrane oxygenation, LMWH, PFA 200, Primary haemostasis,
- MeSH
- Anticoagulants adverse effects MeSH
- Enoxaparin MeSH
- Heparin, Low-Molecular-Weight MeSH
- Heparin adverse effects MeSH
- Hemorrhage etiology MeSH
- Humans MeSH
- Extracorporeal Membrane Oxygenation * adverse effects MeSH
- Thrombosis * etiology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Case Reports MeSH
- Names of Substances
- Anticoagulants MeSH
- Enoxaparin MeSH
- Heparin, Low-Molecular-Weight MeSH
- Heparin MeSH
BACKGROUND: Unfractionated heparin is used worldwide as a standard anticoagulation therapy for extracorporeal membrane oxygenation (ECMO) machines. However, its use brings about significant bleeding and thrombotic complications for critically ill patients. This case report shows that low molecular weight heparin together with ECMO-produced primary haemostasis pathology can be used as an alternative way of ECMO anticoagulation. CASE PRESENTATION: This paper presents the case of a patient with respiratory failure who subsequently suffered from cardiac failure and spent 94 days on combined V-V and V-A ECMO devices (two ECMO devices running simultaneously on one patient) with intravenous enoxaparin used instead of unfractionated heparin anticoagulation. No life-threatening bleeding/thrombotic events happened during this period, nor did any technical problems with ECMO occur. CONCLUSIONS: In this case report, continuous intravenous low molecular weight heparin anticoagulation was used as a safe alternative to ECMO anticoagulation.
See more in PubMed
Esper SA, Welsby IJ, Subramaniam K, et al. Adult extracorporeal membrane oxygenation: an international survey of transfusion and anticoagulation techniques. Vox Sang. 2017;112:443–52. doi: 10.1111/vox.12514. PubMed DOI
Thomas J, Kostousov V, Teruya J. Bleeding and thrombotic complications in the use of extracorporeal membrane oxygenation. Semin Thromb Hemost. 2018;44:20–9. doi: 10.1055/s-0037-1606179. PubMed DOI
Durila M, Vajter J, Garaj M, et al. Acquir Prim Hemost Pathol detected platelet function analyzer 200 seen Dur Extracorpor membrane oxygenation is sufficient prevent circuit thrombosis: pilot study J Heart Lung Transpl. 2020;39:980–2. PubMed
Garaj M, Durila M, Vajter J, et al. Extracorpor membrane oxygenation seems induce impairment Prim Hemost Pathol as measured Multiplate analyzer: observational retrospective study Artif Organs. 2022;46:899–907. PubMed
Nunez JI, Gosling AF, O’Gara B, et al. Bleeding and thrombotic events in adults supported with venovenous extracorporeal membrane oxygenation: an ELSO registry analysis.Intensive Care Med. 2022;48:213–224. PubMed PMC
Chung M, Cabezas FR, Nunez JI, et al. Hemocompatibility-Related Adverse Events and Survival on Venoarterial Extracorporeal Life Support: An ELSO Registry Analysis.JACC Heart Fail. 2020;8:892–902. PubMed PMC
Gao C, Boylan B, Fang J, et al. Heparin promotes platelet responsiveness by potentiating αIIbβ3-mediated outside-in signaling. Blood. 2011;117:4946–52. PubMed PMC
